Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shenzhen Kangtai Biological Products Co., Ltd.
  6. Summary
    300601   CNE100002Q33

SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

(300601)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shenzhen Stock Exchange
06/18/2021 06/21/2021 06/22/2021 06/23/2021 06/24/2021 Date
139.82 137.19 141.63 144.67 143.44 Last
8529079 11121550 10976540 8263067 5327990 Volume
-0.20% -1.88% +3.24% +2.15% -0.85% Change
Estimated financial data (e)
Sales 2021 3 618 M 561 M 561 M
Net income 2021 1 137 M 176 M 176 M
Net cash position 2021 3 327 M 515 M 515 M
P/E ratio 2021 84,7x
Yield 2021 0,20%
Sales 2022 5 521 M 855 M 855 M
Net income 2022 1 809 M 280 M 280 M
Net cash position 2022 3 209 M 497 M 497 M
P/E ratio 2022 52,1x
Yield 2022 0,32%
Capitalization 98 459 M 15 215 M 15 255 M
EV / Sales 2021 26,3x
EV / Sales 2022 17,3x
Nbr of Employees 2 043
Free-Float 95,6%
More Financials
Company
Shenzhen Kangtai Biological Products Co. specialises in the research, development and marketing of human vaccines. Products include vaccines against hepatitis B, haemophilus influenzae type B, measles and rubella. 
Sector
Pharmaceuticals
Calendar
09/02Earnings Release
More about the company
Ratings of Shenzhen Kangtai Biological Products Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
05/31SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : Kangtai Biological to List 1.3 Million Ne..
MT
05/25China's Kangtai Biological, partners agree to run Phase III trial in Chile - ..
RE
05/16SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : China Approves Kangtai Biological's COVID..
MT
02/02MARKET CHATTER : Kangtai Biological to Produce 400 Million AstraZeneca COVID-19 ..
MT
02/02ASTRAZENECA  : China partner expects to be able to make 400 mln COVID-19 vaccine..
RE
2020Fosun Pharma to buy 100 million doses of BioNTech's COVID-19 vaccine for main..
RE
2020China's Rhodiola set to sell and test Russia's Sputnik-V vaccine
RE
2020SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : AstraZeneca's COVID-19 vaccine to begin c..
RE
2020SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : China's Kangtai starts mid-stage trial of..
RE
2020China's Kangtai gets approval for clinical trial of coronavirus vaccine candi..
RE
2020AstraZeneca Sets Deal in China Market -- WSJ
DJ
2020AstraZeneca Strikes Deal to Produce Covid-19 Vaccine for China
DJ
2020AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
2020AstraZeneca in first COVID-19 vaccine deal with Chinese company
RE
2020SHENZHEN KANGTAI BIOLOGICAL PRODUCTS : AstraZeneca in deal with Kangtai Bio to s..
RE
More news
News in other languages on SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.

- No features available -

More news
Chart SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Shenzhen Kangtai Biological Products Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHENZHEN KANGTAI BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 143,44 CNY
Average target price 230,56 CNY
Spread / Average Target 60,7%
EPS Revisions
Managers and Directors
NameTitle
Wei Min Du Chairman & General Manager
Xiang Miao Chief Financial Officer & Board Secretary
Zhi Yun Lu Chairman-Supervisory Board
Xiang Ming Li Independent Director
Dong Guang Ma Independent Director
Sector and Competitors